...
首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Investigation of Galactosylated Low Molecular Weight Chitosan-Coated Liposomes for Cancer Specific Drug Delivery
【24h】

Investigation of Galactosylated Low Molecular Weight Chitosan-Coated Liposomes for Cancer Specific Drug Delivery

机译:半乳糖基化的低分子量壳聚糖包衣脂质体用于癌症特异性药物递送的研究

获取原文

摘要

Purpose: To assess the hepatocyte targeting potential of galactosylated low molecular weight chitosan (Gal-LMWCs)-coated liposomes bearing doxorubicin hydrochloride (DOX). Methods: Chitosan (CS) was depolymerized and lactobionic acid (LA) containing a galactose group was coupled with low molecular weight chitosan (LMWC) using carbodiimide chemistry. Two types of galactosylated polymers with variable degree of substitution were synthesized. Liposomes were prepared using film casting method, coated with the synthesized polymers and characterized for vesicle shape and size, polydispersity, zeta potential, drug entrapment, coating efficiency, in vitro drug release and cytotoxicity on human hepatoma cell line (HepG2). Results: Coating efficiency was greater for the polymer with a lower degree of substitution. The liposomes formed were spherical in shape with a size range of 110 - 160 nm, drug entrapment of 92.14 - 96.37 % and zeta potential of 20.6 - 29.4 mV. Gal-LMWC(s)-coated liposomes exhibited a maximum of 65 % in vitro drug release in 24 h in a sustained fashion. The 50 % inhibitory concentration (IC50) values for liposomal formulations and drug solution were 2.81 and 5.98 μg/ml, respectively. Conclusion: Gal-LMWC (s) coated liposomes containing DOX that demonstrate targetability to human hepatocellular carcinoma cell line ( in vitro ) have been successfully developed.
机译:目的:评估半乳糖基化的低分子量壳聚糖(Gal-LMWCs)涂层的载有盐酸阿霉素的脂质体对肝细胞的靶向潜力。方法:将壳聚糖(CS)解聚,并使用碳二亚胺化学法将含有半乳糖基团的乳糖酸(LA)与低分子量壳聚糖(LMWC)偶联。合成了两种具有不同取代度的半乳糖基化聚合物。使用流延法制备脂质体,用合成的聚合物包衣,并表征囊泡的形状和大小,多分散性,ζ电位,药物截留,包被效率,体外药物释放和对人肝癌细胞系(HepG 2 < / sub>)。结果:具有较低取代度的聚合物的涂层效率更高。形成的脂质体为球形,大小范围为110-160 nm,药物截留率为92.14-96.37%,ζ电位为20.6-29.4 mV。 Gal-LMWC包被的脂质体在24小时内以持续的方式表现出最大65%的体外药物释放。脂质体制剂和药物溶液的50%抑制浓度(IC 50 )值分别为2.81和5.98μg/ ml。结论:已成功开发出具有DOX的Gal-LMWC涂层脂质体,该脂质体具有对人肝癌细胞系(体外)的靶向性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号